July 9, 2015—A controversial study about Medicare Part B spending at 340B hospitals is facing more criticism. … [Read more...]
AstraZeneca, Biogen Idec, and Cephalon Settle Medicaid Rebate Fraud Claims
Agreements with whistleblower and federal, state governments do not address 340BJuly 8, 2015—Pharmaceutical manufacturers AstraZeneca, Biogen Idec, and Cephalon have agreed to pay a combined $55.5 million to settle a whistleblower's claims they defrauded the federal government and 24 states by underpaying Medicaid drug rebates. … [Read more...]
HHS and Hospitals Challenge GAO Conclusions About 340B and Medicare
Analysis doesn't support findings of unnecessary spending, they sayUPDATED July 7, 2015 (Includes reaction from America's Essential Hospitals) July 6, 2015—The Department of Health and Human Services and the association representing 340B hospitals have expressed serious concerns about a study released today by the Government Accountability Office on Medicare Part B spending at 340B hospitals. … [Read more...]
Senate Health Spending Bill Has 340B User Fee
OPA would get a $10.2 million appropriation plus an estimated $7.5 million in feesJune 30, 2015—The U.S. Senate Appropriations Committee included a 340B program user fee in the federal healthcare spending bill it passed last week. … [Read more...]
House Panel Level Funds 340B Program in FY 2016
Urges OPA finish work on ceiling price verification systemJune 26, 2015—The U.S. House Appropriations Committee passed its main annual domestic spending bill this week, which level funds the 340B program in the fiscal year that begins Oct. 1. … [Read more...]
HRSA Gives 340B Hospitals a Head’s Up About Recertification
Office of Pharmacy Affairs is holding a webinar on July 8June 23, 2015—The Health Resources and Services Administration Office of Pharmacy Affairs is holding a webinar on July 8 from noon to 1:00 p.m. Eastern about annual recertification of eligibility for 340B hospitals. … [Read more...]
HRSA Taps OIG to Administer 340B Manufacturer Sanctions
Comments on proposed rule are due Aug. 17June 18, 2015—The 340B program proposed rule formally published yesterday would give the Department of Health and Human Services Office of Inspector General responsibility for administering financial sanctions on drugmakers that overcharge providers knowingly and intentionally. … [Read more...]